COMPANY

Aspen Neuroscience

HQ: San Diego, CA source · aspenneuroscience.com ↗ · West Coast

Keywords: iPSC neurology Parkinson's disease Parkinson Disease ANPD001

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series C · $115M · announced Nov 20, 2025 Company release ↗
Source quote
- Nov 20, 2025 · Company release ↗
  “SAN DIEGO, Nov. 20, 2025 / PRNewswire / — Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round”

Raises announced in these releases: $115M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Nov 20, 2025 Raise Private equity round — Series C: $115M (total, as published), announced Nov 20, 2025. Source: company's own press page. source ↗
Nov 20, 2025 Raise Series C · $115M source ↗
Jan 23, 2024 Trial start 1: Phase 1/2a Study of ANPD001 in Parkinson Disease source ↗

Mar 30, 2027 (ESTIMATED) · 1 · Phase 1/2a Study of ANPD001 in Parkinson Disease · NCT06344026

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $115.0M. Last 2 years.

Nov 20, 2025 Private equity round — Series C: $115M (total, as published), announced Nov 20, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06344026	Phase 1/2a Study of ANPD001 in Parkinson Disease	1	Enrolling by invitation	Jan 23, 2024	Mar 30, 2027 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗
InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗